Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants

Ítems similars

• Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
  per: Lee, Hsin‐Fu, et al.
  Publicat: (2019)
• Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor
  per: Lee, Hsin-Fu, et al.
  Publicat: (2020)
• Young Male Patients with Atrial Fibrillation and CHA(2)DS(2)-VASc Score of 1 May Not Need Anticoagulants: A Nationwide Population-Based Study
  per: Chan, Yi-Hsin, et al.
  Publicat: (2016)
• The CHA(2)DS(2)-VASc Score Predicts Major Bleeding in Non-Valvular Atrial Fibrillation Patients Who Take Oral Anticoagulants
  per: Lee, Kuang-Tso, et al.
  Publicat: (2018)
• Association Between Use of Non–Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation
  per: Chang, Shang-Hung, et al.
  Publicat: (2017)